Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. announced it has begun testing MB-204 in the Oprm 1 m odel of autism in collaboration with Dr. Julie Le Merrer and Dr. Jer e Becker at the iBrain Institute, Tours, France. The company seen immediate effects of MB-204 after a single dose in mouse models of depression, which gives confidence the drug could offer improvements in these autistic behaviours after a short course therapy.